Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001437749-25-012549
Filing Date
2025-04-21
Accepted
2025-04-21 16:45:52
Documents
1
Period of Report
2025-04-17

Document Format Files

Seq Description Document Type Size
1 FORM 4 rdgdoc.html 4  
1 FORM 4 rdgdoc.xml 4 3621
  Complete submission text file 0001437749-25-012549.txt   5214
Mailing Address 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300 AUSTIN TX 78731
Business Address 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300 AUSTIN TX 78731 512-501-2444
CASSAVA SCIENCES INC (Issuer) CIK: 0001069530 (see all company filings)

EIN.: 911911336 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1, SUITE 300 AUSTIN TX 78731
Business Address
Nassif Freda (Reporting) CIK: 0002045036 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-41905 | Film No.: 25853921